As of January 23, 2025, Matinas BioPharma (MTNB) has a market cap of $2.918 million USD. According to our data, Matinas BioPharma is ranked No.9148 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 23, 2025 | $2.92 M |
12.49%
|
Dec 31, 2024 | $2.59 M |
-95.28%
|
Dec 29, 2023 | $54.94 M |
-56.80%
|
Dec 30, 2022 | $0.13 B |
-50.50%
|
Dec 31, 2021 | $0.26 B |
-25.74%
|
Dec 31, 2020 | $0.35 B |
-40.09%
|
Dec 31, 2019 | $0.58 B |
281.51%
|
Dec 31, 2018 | $0.15 B |
-48.71%
|
Dec 29, 2017 | $0.30 B |
-17.14%
|
Dec 30, 2016 | $0.36 B |
64.71%
|
Dec 31, 2015 | $0.22 B |
88.89%
|
Dec 31, 2014 | $0.11 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Amarin Corporation
AMRN
|
$0.22 B |
0.000 M
|
Ireland
|
Acasti Pharma
ACST
|
$34.17 M |
-3.448 M
|
Canada
|
Corbus Pharmaceuticals
CRBP
|
$0.14 B |
-0.000 M
|
USA
|
Lipocine
LPCN
|
$23.48 M |
0.000 M
|
USA
|
Esperion Therapeutics
ESPR
|
$0.43 B |
-0.000 M
|
USA
|
Arrowhead Pharmaceuticals
ARWR
|
$2.45 B |
-0.000 M
|
USA
|
Viking Therapeutics
VKTX
|
$3.79 B |
-0.000 M
|
USA
|
Akebia Therapeutics
AKBA
|
$0.52 B |
0.000 M
|
USA
|
Omeros Corporation
OMER
|
$0.54 B |
0.000 M
|
USA
|
Spero Therapeutics
SPRO
|
$47.65 M |
0.000 M
|
USA
|
Ultragenyx
RARE
|
$3.97 B |
0.000 M
|
USA
|
Market Cap | = | MTNB Stock Price | * | MTNB Shares Outstanding |
= | $0.57 | * | 5.09 M | |
= | $2.92 M |